证券代码：301234 证券简称：五洲医疗 公告编号：2024-026 安徽宏宇五洲医疗器械股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）2023 年度利润分 配方案已获 2024 年 5 月 13 日召开的公司 2023 年年度股东大会审议通过，现将 权益分派事宜公告如下： 一、2023 年度利润分配方案情况 1、利润分配方案基本情况 2024 年 5 月 13 日，公司 2023 年年度股东大会审议通过公司 2023 年度利 润分配方案：以截至 2023 年 12 月 31 日的公司总股本 68,000,000 股为基数，向 公司全体股东每 10 股派发现金股利 4.00 元人民币（含税），共分配现金股利 27,200,000 元（含税），本次利润分配不送红股，不以资本公积金转增股本，剩 余未分配利润结转至下一年度。本次利润分配方案实施前，公司总股本发生变化， 将按现金股利总额不变的原则，按比例调整每股现金股利金额。 2、利润分配方案其他情况 （1）公司 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2024-025 安徽宏宇五洲医疗器械股份有限公司 关于使用部分闲置募集资金现金管理和闲置自有资金 委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或者重大遗漏。 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日召开第三届董事会第二次会议和第三届监事会第二次会议审议通过了《关 于使用部分闲置募集资金现金管理的议案》《关于使用部分闲置自有资金委托 理财的议案》。公司董事会、监事会同意在确保不影响公司正常运营和募集资 金投资项目推进的情况下，接续 2023 年第二次临时股东大会关于使用部分闲置 募集资金现金管理和自有资金委托理财的授权，使用任一时点余额不超过人民 币 4,000 万元的暂时闲置募集资金开展现金管理，并使用任一时点余额不超过 人民币 20,000 万元的暂时闲置自有资金开展委托理财。在上述额度范围内，现 金管理和委托理财资金可以滚动使用。本次现金管理和委托理财授权期限自公 司董事会审议通过之日起 12 个月内，或公司董事会在上述期限内再次审议通过 相关议 ...

2023 年年度股东大会法律意见书 天律意 2024 第 01150 号 致：安徽宏宇五洲医疗器械股份有限公司 根据《中华人民共和国公司法》(下称《公司法》)、《中华人民共和国证券 法》（下称《证券法》）、中国证券监督管理委员会《上市公司股东大会规则》 （下称《股东大会规则》）、《深圳证券交易所上市公司股东大会网络投票实施 细则（2020 年修订）》《安徽宏宇五洲医疗器械股份有限公司公司章程》（下 称《公司章程》）等相关规定，以及贵公司（下称公司）与安徽天禾律师事务所 （下称本所）签订的《法律顾问合同》，本所律师出席公司 2023 年年度股东大 会，并对本次股东大会相关事项进行了见证，出具本法律意见书。 安徽天禾律师事务所 关于安徽宏宇五洲医疗器械股份有限公司 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用的原则，对本次股东大会所涉及的相关 事项进行了必要的核查和验证，核查了本所认为出具本法律意见书所需的相关文 件和资料。为出具本法律意见，本所律师审查了公司提供的以下文件： 1、《 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2024-023 安徽宏宇五洲医疗器械股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次股东大会采用现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议通知情况 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）2023 年年度股 东大会通知于 2024 年 4 月 16 日在巨潮资讯网（http://www.cninfo.com.cn）以公 告形式发出。 2、会议召开方式：采用现场投票与网络投票相结合的方式 3、召开时间： （1）现场会议召开时间：2024 年 5 月 13 日（星期一）下午 14：00 （2）网络投票时间：2024 年 5 月 13 日 其中，通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 5 月 13 日（星期一）上午 9:15-9:25，9:30-11:30，下午 13: ...

光大证券股份有限公司关于安徽宏宇五洲医疗器械股份有限公司 2023年度持续督导跟踪报告 | | 月 日届满，但未能及时完成换届选举，存 18 | | --- | --- | | | 在超期履职和部分独董连续任职超过 年的 6 | | | 情况；经保荐机构提醒，公司已于 2023 年 11 | | | 月完成整改。 | | | 保荐机构提请公司关注：公司及董监高人员应 | | | 在今后不断加强证券法律法规的学习和培训， 不断提高履职能力，忠实勤勉、谨慎履职，提 | | | 高公司规范运作水平，完善公司治理。 | | 6.发表专项意见情况 | | | （1）发表专项意见次数 | 次 9 | | （2）发表非同意意见所涉问题及结论意见 | 无 | | 7.向本所报告情况（现场检查报告除外） | | | （1）向本所报告的次数 | 次 0 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8．关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 无 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | 不适用 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2024-022 安徽宏宇五洲医疗器械股份有限公司 关于取得专利授权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或者重大遗漏。 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）于 2024 年 5 月 7 日取得国家知识产权局《发明专利证书》，公司医疗器械产品"一种智能型自动 加载高压无针注射器"取得发明专利授权，现将有关情况公告如下： 一、专利授权基本情况 公司本次取得发明专利授权的产品"一种智能型自动加载高压无针注射器" 涉及医疗器械技术领域，具体是一种智能型自动加载高压无针注射器。本发明利 用动力源产生的瞬时高压使注射器内药物（液体或冻干粉）通过喷嘴形成高速、 高压的喷射流（流速一般大于 100m/s），从而使药物穿透皮肤外层到皮下、皮内 等组织层释放药效，其特点主要是自动抽取及加压注射液，无注射针注射，减少 了患者的痛感。 截至本公告披露日，公司上述发明专利涉及的技术和产品尚未上市销售。 二、专利授权对公司的影响 公司医疗器械产品"一种智能型自动加载高压无针注射器"取得发明专利授 权，有利于公司发 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2024-022 安徽宏宇五洲医疗器械股份有限公司 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日召开第三届董事会第二次会议和第三届监事会第二次会议审议通过了《关 于使用部分闲置募集资金现金管理的议案》《关于使用部分闲置自有资金委托 理财的议案》。公司董事会、监事会同意公司在确保不影响公司正常运营和募 集资金投资项目推进的情况下，接续 2023 年第二次临时股东大会关于使用部分 闲置募集资金现金管理和自有资金委托理财的授权，使用任一时点余额不超过 人民币 4,000 万元的暂时闲置募集资金开展现金管理，并使用任一时点余额不 超过人民币 20,000 万元的暂时闲置自有资金开展委托理财。在上述额度范围内， 现金管理和委托理财资金可以滚动使用。本次现金管理和委托理财授权期限自 公司董事会审议通过之日起 12 个月内，或公司董事会在上述期限内再次审议通 过相关议案时止。具体内容详见公司于 2024 年 4 月 16 日在巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 截至 2024 年 4 月 24 日 ...

RSM 容诚 审计报告 安徽宏宇五洲医疗器械股份有限公司 容诚审字[2024]230Z0569 号 容诚会计师事务所(特殊普通合伙) 中国 · 北京 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查 "社行" | 序号 | 内 容 | 页码 | | --- | --- | --- | | 1 | 审计报告 | 1-6 | | 2 | 合并资产负债表 | 7 | | 3 | 合并利润表 | 8 | | 4 | 合并现金流量表 | 9 | | 5 | 合并所有者权益变动表 | 10 - 11 | | 6 | 母公司资产负债表 | 12 | | 7 | 母公司利润表 | 13 | | 8 | 母公司现金流量表 | 14 | | 9 | 母公司所有者权益变动表 | 15 - 16 | | 10 | 财务报表附注 | 17- 121 | 录 审计报告 容诚审字[2024]230Z056 安徽宏宇五洲医疗器械股份有限公司全体股东: 一、审计意见 我们审计了安徽宏宇五洲医疗器械股份有限公司(以下简称五洲医疗)财务 报表,包括 2023年 12 月 31 日的合并及 ...

安徽宏宇五洲医疗器械股份有限公司 独立董事 2023 年度述职报告 安徽宏宇五洲医疗器械股份有限公司董事会 二〇二三年四月十五日 | 独立董事 2023 年度述职报告目录 1 | | --- | | 王清刚 2 | | 娄亦捷 9 | | 郑晓风 15 | | 顾光（离任） 21 | | 李玉文（离任） 28 | 独立董事 2023 年度述职报告 安徽宏宇五洲医疗器械股份有限公司 安徽宏宇五洲医疗器械股份有限公司 独立董事 2023 年度述职报告 王清刚 尊敬的各位股东及股东授权代表： 本人作为安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"） 独立董事，根据《公司法》《上市公司治理准则》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等法律法规及《公司章程》《公司独 立董事制度》等要求，忠实、勤勉、独立履行独立董事职责，积极出 席相关会议，认真审议董事会各项议案，监督公司规范运作情况，充 分发挥独立董事的作用，切实维护公司和全体股东利益，特别是中小 股东的合法权益。现将本人 2023 年度履行公司独立董事职责情况汇 报如下： 一、独立董事的 ...

Shareholder Structure - The total number of ordinary shareholders at the end of the reporting period was 8,562[5] - Huang Fan holds 24.16% of the shares, totaling 16,429,650 shares[5] - Xiang Bingyi holds 20.25% of the shares, totaling 13,770,000 shares[5] - Zhang Hongyu holds 9.00% of the shares, totaling 6,120,000 shares[5] - Zou Aiying holds 6.00% of the shares, totaling 4,080,000 shares[5] - Taihu Honghui Medical Management Partnership holds 5.24% of the shares, totaling 3,562,350 shares[5] - Zhang Liang holds 3.75% of the shares, totaling 2,550,000 shares[5] - Chen Xiaoru holds 2.25% of the shares, totaling 1,530,000 shares[5] - Liu Yueye holds 0.75% of the shares, totaling 510,000 shares[5] - Zhou Lexiang holds 0.75% of the shares, totaling 510,000 shares[5] Financial Performance - The company's non-recurring gains and losses for 2023 amounted to RMB 5,229,662.99, a decrease from RMB 9,071,340.43 in 2022[26] - Government subsidies included in current profits for 2023 were RMB 4,750,864.76, significantly lower than RMB 19,093,425.33 in 2022[26] - Revenue for 2023 was 533.68 million yuan, a decrease of 2.46% compared to 547.11 million yuan in 2022[82] - Net profit attributable to shareholders in 2023 was 60.27 million yuan, a decrease of 15.04% compared to 70.93 million yuan in 2022[82] - Revenue from syringe products decreased by 4.04% to 218.88 million yuan, accounting for 41.01% of total revenue[84] - Revenue from medical puncture needles decreased by 18.37% to 155.25 million yuan, accounting for 29.09% of total revenue[84] - Revenue from infusion and transfusion sets increased by 18.33% to 92.77 million yuan, accounting for 17.38% of total revenue[84] - Overseas revenue accounted for 97.42% of total revenue, amounting to 519.93 million yuan, a decrease of 2.09% year-on-year[84] - Total revenue for 2023 was RMB 533.68 million, a decrease of 2.46% compared to RMB 547.11 million in 2022[108] - Net profit for 2023 was RMB 60.27 million, a decrease of 15.03% compared to RMB 70.93 million in 2022[109] - R&D expenses for 2023 were RMB 13.48 million, an increase of 2.96% compared to RMB 13.09 million in 2022[108] - Total revenue for 2023 was 389,815,623.68 yuan, a decrease from 415,280,783.39 yuan in 2022[125] - Operating costs for 2023 were 300,813,193.41 yuan, down from 318,151,631.78 yuan in 2022[125] - R&D expenses for 2023 increased to 13,478,535.30 yuan from 13,091,362.65 yuan in 2022[125] - Net cash flow from operating activities in 2023 was 271,319,873.54 yuan, up from 104,165,392.23 yuan in 2022[118] - Total assets as of December 31, 2023, were 848,178,419.23 yuan, compared to 844,597,231.04 yuan at the beginning of the year[118] - Fixed assets increased significantly to 304,661,292.44 yuan in 2023 from 169,364,723.51 yuan in 2022[118] - Total liabilities decreased to 98,470,621.61 yuan in 2023 from 121,154,488.86 yuan in 2022[120] - Net profit attributable to the parent company in 2023 was 258,604,782.29 yuan, up from 237,065,810.34 yuan in 2022[120] - The company's financial expenses in 2023 were -5,099,986.02 yuan, compared to -4,423,214.67 yuan in 2022[125] - The company's total equity as of December 31, 2023, was 749,707,797.62 yuan, up from 723,442,742.18 yuan at the beginning of the year[120] - The company's R&D investment in 2023 was RMB 13,478,535.30, accounting for 2.53% of the operating revenue, an increase from 2.39% in 2022[132] Industry and Market Overview - The company operates in the medical device manufacturing industry, specifically focusing on disposable sterile infusion medical consumables, with sales networks covering over 80 countries and regions[28] - The company has established a comprehensive technological R&D and quality assurance system, with international customer resource advantages[28] - The Chinese government issued 4 new policies and regulations affecting the medical device industry in 2023, including the "Medical Device Emergency Use Management Regulations (Trial)" and the "High-Quality Development Action Plan for the Pharmaceutical Industry (2023-2025)"[29] - The EU revised MDR and IVDR regulations in March 2023 to address medical device shortages[36] - The US FDA released an updated 510(k) program plan in September 2023 to strengthen premarket notification procedures and encourage innovative technologies[37] - The medical consumables industry has reached a mature stage, with stable global demand growth and China's competitive advantage in manufacturing[28] - The company's main business is the R&D, manufacturing, and sales of disposable sterile infusion medical devices, with a focus on the "ODM + integrated supply" model to meet the one-stop procurement needs of international medical device brand owners[38] - The company's main products include syringes, infusion and transfusion sets, medical puncture needles, and other diagnostic and clinical care products, covering a wide range of medical applications[40] - The company's sales model is primarily export-oriented, with domestic sales as a supplement, and it collaborates with international medical device brand owners through ODM[41] - The company's 2023 annual revenue was RMB 533,679,925.02, primarily from the R&D, production, and sales of medical puncture devices, including syringes, infusion and transfusion sets, and puncture needles[63] - The company's products are sold in over 80 countries and regions across Asia, Europe, and the Americas, with a stable customer base of over 300 clients[48] - The company has established a competitive advantage in the disposable sterile infusion medical device segment through continuous innovation, quality improvement, and optimized production processes[49] - The company's internal performance drivers include a well-established R&D and quality assurance system, while external drivers include global economic growth, population aging, and increasing demand for medical consumables[42] - The global medical consumables industry is in a mature stage, with stable growth in demand, particularly in developing countries due to improved healthcare conditions[46] - The company has a strong reputation in the traditional infusion product market, supported by automated production equipment, mature production processes, and a robust quality control system[48] - The company operates in over 80 countries and regions across Asia, Europe, and the Americas, primarily through an "ODM + integrated supply" model to meet the one-stop procurement needs of international medical device brands[198] R&D and Innovation - The company obtained 12 utility model patents and 2 design patents in 2023, and 3 products received FDA approval[83] - As of the end of 2023, the company held 92 patents, including 1 invention patent, 77 utility model patents, and 14 design patents[83] - The company completed product design development and registration for multiple new products, including safety infusion needles and self-destruct syringes[97] - The company is in the design conversion and verification phase for several new products, such as central venous catheters and PICC lines[97] - The company terminated the development of disposable dental needles[97] - The company is focusing on expanding its product line and enhancing product competitiveness through new product development[97] - The company obtained 3 FDA product registrations in 2023, bringing the total number of medical device registrations and certifications to 47, including 11 domestic registrations, 16 CE certifications, and 20 FDA registrations[135] - The company is developing a fully automatic rebound blood collection needle, which is in the registration stage and aims to enhance product competitiveness[131] - The company is in the design input phase for an automatic rebound insulin safety injection needle, which is expected to expand the product line and improve competitiveness[131] - The company is developing a safety protection needle for disposable drug delivery devices, which is in the design input phase and aims to expand the product line[131] - The company is in the pilot verification stage for an improved precision syringe with additional support, which is expected to add product functionality and expand the product line[131] - The company is developing a safety protection needle for venous blood collection, which is in the design conversion and verification phase and aims to expand the product line[131] - The company is implementing intelligent transformation in medical device production and material delivery processes, which is expected to reduce labor costs and improve product quality[131] - The company is in the design conversion and verification phase for a universal injection needle with safety protection, which aims to expand the product line[131] - The company has established a research and development system that matches its business needs, with a mechanism for human resource reserve, training, and introduction, ensuring no significant adverse impact on core competitiveness[134] Quality Control and Compliance - The company's accounts receivable recoverability was identified as a key audit matter, with specific procedures implemented to assess the reasonableness of assumptions and estimates[24] - The company reported no differences in net profit and net assets between Chinese and international accounting standards[25] - The company has established a comprehensive quality control system in compliance with international standards, including EU MDD and US FDA QSR 820 regulations[185] - The company has 16 types of sterile disposable medical devices registered in China, all classified as Class IIa, with certificates valid until December 31, 2028[138] - The company has 13 types of medical devices registered with the FDA, including Class I and Class II devices, with some registrations dating back to 2021[140] - The company's FDA-registered devices include insulin syringes, blood collection sets, and safety hypodermic needles, with some registrations as recent as April 12, 2022[140] - The company's sterile disposable devices in China include insulin syringes, blood transfusion sets, and dental injection needles, all with a 5-year validity period[138] - The company's FDA-registered devices include dental irrigation syringes and vacuum blood collection sets, with some registrations dating back to 2021[140] - The company's sterile disposable devices in China include precision flow regulators and safety blood collection needles, all with a 5-year validity period[138] - The company's FDA-registered devices include safety hypodermic needles with syringes, with registrations dating back to October 4, 2021[140] - The company's sterile disposable devices in China include intravenous needles and infusion sets, all with a 5-year validity period[138] - The company's FDA-registered devices include insulin pen needles and blood collection needle holders, with some registrations dating back to 2021[140] - The company's sterile disposable devices in China include sterile dental injection needles and safety hypodermic needles, all with a 5-year validity period[138] Operational Efficiency and Costs - Sales volume decreased by 21.26% to 575,737.63 thousand units in 2023 compared to 731,170.38 thousand units in 2022[88] - Production volume decreased by 23.47% to 564,814.82 thousand units in 2023 compared to 738,006.08 thousand units in 2022[88] - Inventory volume decreased by 19.11% to 46,227.84 thousand units in 2023 compared to 57,150.65 thousand units in 2022[88] - Direct material costs decreased by 3.94% to 293,112,050.18 yuan, accounting for 69.80% of total operating costs in 2023[90] - Manufacturing expenses increased by 19.60% to 63,370,694.80 yuan, accounting for 15.09% of total operating costs in 2023[90] - Top 5 customers accounted for 29.02% of total annual sales, with total sales of 154,918,858.61 yuan in 2023[92] - Top 5 suppliers accounted for 32.62% of total annual purchases, with total purchases of 122,902,131.75 yuan in 2023[92] - Sales expenses increased by 17.06% to 15,305,821.92 yuan in 2023 compared to 13,075,299.05 yuan in 2022[94] - Management expenses decreased by 34.03% to 19,946,827.57 yuan in 2023 compared to 30,237,924.18 yuan in 2022[94] - R&D expenses increased by 2.96% to 13,478,535.30 yuan in 2023 compared to 13,091,362.65 yuan in 2022[94] - The number of R&D personnel decreased by 5.00% to 95 in 2023 from 100 in 2022[99] - The proportion of R&D personnel with a bachelor's degree decreased by 12.50% to 14 in 2023 from 16 in 2022[99] - The company's financial expenses decreased to RMB -8.02 million in 2023 from RMB -7.86 million in 2022, primarily due to increased interest income[108] - The company has achieved automated production in key processes such as feeding, injection molding, and sterilization, improving production efficiency and reducing costs[78] Strategic Plans and Risks - The company plans to focus on four key areas in 2024: implementation of fundraising projects, R&D of new technologies and products, promotion of lean manufacturing, and development of customer and market systems[177] - The company faces risks such as intensified market competition, fluctuations in raw material prices, quality control issues, high reliance on export revenue, and exchange rate risks[183][184][185][186][187] - The company aims to improve its competitiveness by developing new technologies and products, enhancing product quality, and optimizing manufacturing costs[183] - To mitigate raw material price risks, the company will monitor market trends and adjust procurement strategies accordingly[184] - To reduce reliance on export revenue, the company plans to increase domestic market share and gradually raise the proportion of domestic sales[186] - The company will use forward exchange contracts to hedge against potential losses caused by RMB exchange rate fluctuations[187] - The company has not identified any issues affecting its ability to continue operations for the next 12 months, and it is reasonable to prepare financial statements on a going concern basis[200] Subsidiaries and Investments - Anhui Hongyu Wuzhou Import and Export Co., Ltd., established in September 2016, is a subsidiary primarily engaged in the export of medical devices, forming part of the company's main business[148] - The company's subsidiary, Anhui Hongyu Wuzhou Import & Export Co., Ltd., reported total assets of 129,918,558.17 yuan, net assets of 93,951,647.62 yuan, and operating revenue of 321,287,831.72 yuan[178] - The company's over-raised funds amount to 62.54 million yuan, with 18 million yuan permanently supplementing working capital and 44.54 million yuan used for the "Disposable Infusion Puncture Medical Device Technical Transformation and Expansion Project"[145] - As of December 31, 2023, the company has used 33.12 million yuan of over-raised funds for the "Disposable Infusion Puncture Medical Device Technical Transformation and Expansion Project"[145] - The company has pre-invested 143.87 million yuan in fundraising projects and 10.07 million yuan in issuance fees, with a total of 153.94 million yuan replaced by raised funds[145] - Unused raised funds include 22.90 million yuan in special fundraising accounts and 25 million yuan in cash management[146] - The company's total equity at the end of the previous year was 262,769,800.56 yuan, with a capital reserve of 22,510,275.27 yuan and undistributed profits of 171,768,569.20 yuan[163] - During the current period, the company increased its capital by 17,000,000.00 yuan and raised additional capital of 372,742,391.76 yuan, resulting in a total increase in equity of 389,742,391.76 yuan[164] - The company's comprehensive income for the period was 70,930,549.86 yuan, contributing to the overall increase in equity[164] - The company's total equity at the beginning of the current year was 652,495,315.10 yuan, with a capital reserve of 395,252,667.03 yuan and undistributed profits of 166,118,383.26 yuan[165] - The company's comprehensive income for the current year was 47,260,834.90 yuan, contributing to the overall increase in equity[165] - The company's total owner's equity at the end of the period was 652,495,315.10 yuan, with a capital reserve of 395,252,667.03 yuan and retained earnings of 166,118,383.26 yuan[169] Market and Customer Relationships - The company has established stable cooperative relationships with well-known medical device brand companies in over 80 countries and regions[76] - The company's total share capital is 51 million shares, with Huang Fan holding the largest share at 1,642,970 shares, representing 32.22% of the total[196]